1. Outcomes of Intravitreal Bevacizumab in Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease- A Prospective Study.
- Author
-
Sakata VM, Morita C, Lavezzo MM, Rodriguez EEC, Abdallah SF, Pimentel SLG, Hirata CE, and Yamamoto JH
- Subjects
- Adult, Choroidal Neovascularization etiology, Choroidal Neovascularization physiopathology, Female, Fluorescein Angiography, Follow-Up Studies, Humans, Intravitreal Injections, Middle Aged, Prospective Studies, Subretinal Fluid, Tomography, Optical Coherence, Treatment Outcome, Uveomeningoencephalitic Syndrome physiopathology, Vascular Endothelial Growth Factor A antagonists & inhibitors, Visual Acuity physiology, Angiogenesis Inhibitors therapeutic use, Bevacizumab therapeutic use, Choroidal Neovascularization drug therapy, Uveomeningoencephalitic Syndrome complications
- Abstract
Purpose : To assess the effectiveness of intravitreal (IV) bevacizumab and the need for systemic immunosuppressive therapy (IMT) in choroidal neovascularization (CNV) in Vogt-Koyanagi-Harada disease (VKHD). Methods : CNV treatment consisted of three monthly IV bevacizumab injections as a loading dose; if intra/subretinal fluid (IRF) persisted, further injections were proceeded besides increment in systemic IMT. Outcome analyses at 3, 6, and 12 months were visual acuity, central foveal thickness, macular volume, IRF, and addition of IMT. Results : Seven eyes of six patients were included. Five patients (five eyes) completed a 12-month follow-up and received 12 IV bevacizumab injections. At the 12-month follow-up, visual acuity improved in four out of five eyes ( p = .0568); all eyes had decreased macular volume ( p = .0431) but they still had persistent IRF; and all cases needed IMT introduction/increment. Conclusion : Intravitreal bevacizumab in association with systemic IMT was effective for CNV in VKHD. Active CNV may indicate disease of inadequate clinical control.
- Published
- 2021
- Full Text
- View/download PDF